logo

For the Inventor, By the Inventor

Andover, MA, United States of America

Hyeong-wook Choi

This inventor holds 23 USPTO granted patents and 5 published patent applications and 10 EPO patents, primarily in Cancer Treatment. Top assignees: Eisai R&d Management Co., Ltd., Otsuka Pharmaceutical Company, Limited, Epizyme, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyeong-wook Choi. Retrieved from https://idiyas.com/inventor/hyeong-wook-choi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 63(Granted Patents)


Company Filing History:

goldMedal20 out of 530 
 
Eisai R&d Management Co., Ltd.
 patents
silverMedal3 out of 846 
 
Otsuka Pharmaceutical Company, Limited
 patents
bronzeMedal1 out of 159 
 
Epizyme, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Bladder Cancer
Halichondrin B
Macrocyclization
EP4 Antagonists
Cancer Treatment
Synthetic Route
Polypropionates
Stereochemistry
23 patents (USPTO):Explore Patents
1. 12251394 - Methods for the treatment of bladder cancer (2025-03-18),
2. 11643418 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2023-05-09),
3. 11542269 - Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof (2023-01-03),
4. 11434246 - EP4 antagonists (2022-09-06),
5. 11339188 - Compounds for the treatment of cancer (2022-05-24),
6. 11136335 - Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof (2021-10-05),
7. 11028119 - Synthetic route to 2'-deoxy-2′,2′-difluorotetrahydrouridines (2021-06-08),
8. 10941148 - EP4 antagonists (2021-03-09),
9. 10934307 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2021-03-02),
10. 10913749 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides (2021-02-09),
11. 10793581 - Stereochemically defined polypropionates and methods for making and using the same (2020-10-06),
12. 10618930 - Compounds for the treatment of cancer (2020-04-14),
13. 10611773 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2020-04-07),
14. 10526362 - Synthetic route to 2'-deoxy-2′,2′-difluorotetrahydrouridines (2020-01-07),
15. 10407439 - Stereochemically defined polypropionates and methods for making and using the same (2019-09-10),

Title: Inventor Hyeong-wook Choi: Pioneering Innovations in Andover

Introduction: Hyeong-wook Choi is a distinguished inventor based in Andover, MA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Hyeong-wook Choi holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Choi has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Hyeong-wook Choi has collaborated with top engineers, scientists, and researchers, fostering a culture of innovation and excellence in all his projects.

Conclusion: Inventor Hyeong-wook Choi's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true pioneer in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…